Hints and tips:
Related Special Reports
...AstraZeneca makes 40 per cent of its sales in the US, like many European pharmaceutical companies, and it has sought to justify the increases by comparing Soriot’s pay with US pharma bosses....
...Tirzepatide’s list price is $1,060 for four weeks of supply....
...Drugs companies issued 1,643 warnings of impending shortages in 2023, compared to 648 in 2020, the research found....
...The drugs mimic the GLP-1 gut hormone to trigger the release of insulin....
...For that reason, the 2023 FT Person of the Year went to Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, the pharmaceutical company that brought these successful weight-loss drugs to market....
...Finding an effective treatment for Alzheimer’s has proved fiendishly difficult for drug companies, and previous regulatory decisions in the field have stirred controversy....
...Orchard Therapeutics’ Lenmeldy this week became the first US approved medicine for metachromatic leukodystrophy (MLD), a fatal genetic disorder affecting an average of 40 new-born babies a year in the US...
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...But according to Holst, who has worked as a consultant for the company, it has struggled to develop small-molecule GLP-1 drugs, which are much easier and cheaper for manufacturers to produce at scale....
...Scotland approved the drug in December. It has a list price of £1,455 per vial, although it is available to the NHS at an undisclosed discount....
...The company has genetically validated two other drug targets....
...A Nasdaq index of small cap biotech stocks has rallied by more than 40 per cent in the past three months as investors bet on an end to interest rate rises....
...About 1,000 people in England would have been eligible for the treatment, according to estimates by the watchdog and companies....
...In addition, the company said it was progressing towards US approval of an innovative cancer drug Datopotamab deruxtecan for the treatment of patients with advanced lung cancer....
...company....
...Swiss pharmaceutical company Roche is conducting phase 1 clinical trials on an antibiotic that successfully targeted a Gram-negative bacterium known as carbapenem-resistant Acinetobacter baumannii, or Crab...
...Hong Kong-based activist fund Oasis Management has bought a 9.6 per cent stake in the company, which has a market value of $1.2bn....
...Currently there are more than 100 GLP-1 pipeline drugs under development. These locally-made drugs are not far off hitting the market....
...The company plans to “move forward as quickly as possible” with further trials in MASH for the drug....
...In Jørgensen’s native Denmark, he said that about 1.5 per cent of the adult population, just under 100,000 Danes, are paying for the drug....
...The company expects the acquisitions to increase its capacity to make drugs, including Ozempic and Wegovy, from 2026 onwards....
...The Danish group revealed plans in November to spend $6bn expanding the 1.2mn square metre production site in Denmark where it makes semaglutide, the active ingredient in both Wegovy and Ozempic....
...Although Amazon automatically applies manufacturer coupons to orders, which lowers the price for customers, the drugs still carry a hefty pricetag of more than $1,000 for four doses....
...In a bright spot, Pfizer reported adjusted earnings per share of $1.87, surpassing analyst estimates for earnings of $1.55....
...Curaleaf is the world’s largest cannabis company, with a market capitalisation of C$4.6bn, and its shares have risen 40 per cent in the past year....
International Edition